Diet and lifestyle

The study links a common compound in plant foods (oxalate) to intestinal inflammation in IBD, suggesting diet and oxalate metabolism may be modifiable contributors to flares.

The work helps explain why smoking increases Crohn’s risk but seems protective for ulcerative colitis by identifying genetic loci and smoking-dependent gene expression changes that differ between the two diseases. That...

The gut–liver axis links intestinal inflammation to liver disturbances in IBD. This preclinical study suggests a specific oat β‑glucan fraction reduced liver oxidative stress and inflammation in rats with chemically...

IBD patients often have depression and anxiety that current anti-TNF biologics do not adequately treat. An engineered probiotic that both neutralizes local TNFα and promotes GABA-producing microbes could address...

This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...

People with Crohn's disease often ask whether food additives and artificial sweeteners affect gut microbes or disease activity. This trial directly tests whether sucralose changes the fecal microbiome in adults with...

Parents and clinicians often worry that when solids are started might change a child’s future risk of IBD. This large prospective study found no clear link between timing or patterns of complementary feeding and later...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Cell Biology and...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Diet and lifestyle. The original article is from European Journal of Integrative Medicine.

The study identifies an A. muciniphila strain (WW001) that strengthened barrier function and reduced inflammation in lab and mouse models of colitis, pointing to a possible microbiome-based probiotic strategy for IBD...

Many people with Crohn’s are given dietary limits (here, ~30 g fat/day) after flares or hospitalization. Practical, sustainable food-choice strategies can help patients follow such advice and reduce meal-related stress.

FMT is an active area of research that could affect future IBD treatments; patients with IBD commonly experience obesity and complex care decisions. Updates on FDA-approved FMT products and ongoing Crohn’s studies may...

Routinely collected healthcare data can reveal how Crohn’s disease is managed and experienced in everyday practice, helping fill gaps left by clinical trials. A broader, data-driven measure of disease burden could better...

Organoid models aim to reproduce human intestinal biology more closely than traditional cell lines or animal models, which could improve understanding of IBD mechanisms and help develop or personalize therapies.

The study shows functional differences in how Crohn’s versus healthy fecal microbiota ferment substrates, with CD cultures making less beneficial butyrate and more ethanol/amino acids. That could inform future...

The study links macrophage CD38-driven NAD depletion to intestinal inflammation and shows that restoring NAD or blocking CD38 reduced disease in experimental colitis—suggesting a new metabolic target for IBD therapies.

A microbiome-targeted, food-grade supplement could offer a non-immunosuppressive option for people with mild-to-moderate ulcerative colitis who remain inflamed or want to delay immunosuppressive/biologic therapy. The...

IUS offers a rapid, radiation-free way to detect active inflammation and common complications in IBD, which could improve initial ED assessment and reduce reliance on CT scans.

IBD and obstructive sleep apnea may influence each other through shared biological processes (barrier dysfunction, dysbiosis, immune activation, intermittent hypoxia), so understanding this could affect screening and...

OTC painkiller use is very common among people with IBD, and those with recent disease activity are more likely to use them frequently and to take them specifically for IBD-related pain. Knowing this can help clinicians...

Viruses in the gut (including bacteriophages) could influence inflammation and the intestinal barrier in IBD, so understanding the virome may point to new research directions or therapies.

The article reports a new oral nanozyme that combines imaging and ROS-scavenging therapy aimed at IBD lesions—an early-stage approach that could one day enable targeted, noninvasive treatment and lesion tracking.

The study reports that Chlorella-derived polysaccharide AHP reduced inflammation, supported barrier repair, and changed gut microbiota in cell and mouse colitis models—suggesting a potential new bioactive candidate for...

Phase angle, an easy-to-measure BIA parameter, was lower in IBD patients with malnutrition and higher disease activity. Detecting malnutrition earlier could matter for patients' strength, healing, and overall outcomes.

The study suggests a bacterial lysate and L-arginine can restore intestinal barrier function in cell and mouse models — a process that could be relevant to IBD because barrier dysfunction contributes to disease activity.

Nanoencapsulated flavonoids are proposed as a way to improve delivery of biologically active dietary compounds to the inflamed gut in IBD; a rational design framework could accelerate translation from bench research to...

The study suggests that serum zinc by itself may not be a reliable indicator of endoscopic inflammation in UC; nutritional status and inflammation (for example albumin and CRP) can confound zinc levels.

Work-related productivity loss was common in this study and linked to both clinical (disease activity, strictures, fatigue) and psychosocial factors (anxiety, depression, self-efficacy, social support).

If creeping fat and mesenteric inflammation matter in your Crohn’s disease, this study suggests a new mechanism linking adipocyte autophagy to proinflammatory lipid mediators (oxylipins) and local immune activation —...

Understanding how individual diet and microbiome patterns relate to disease activity could help create personalized dietary approaches for children with Crohn's disease and improve monitoring using home fecal...

Malnutrition is common in people with IBD and worsens outcomes. This study suggests that high-protein diets, especially when paired with enteral supplements, can improve nutritional status and may also reduce disease...

An animal study found two probiotic strains reduced inflammation and inflammasome markers in an experimental ulcerative colitis model, which could inform veterinary treatments and early-stage research relevant to IBD.

FibroScan detects liver fibrosis and steatosis that are common and sometimes under-recognized in people with IBD; identifying liver disease earlier could change monitoring or referral decisions, especially for patients...

The study suggests that correcting low vitamin D in people with IBD may shift immune responses toward tolerance of gut microbes and associate with lower inflammation—information that could affect monitoring and...

Self-management programs that teach cognitive behavioral strategies, symptom tracking, relaxation, sleep and diet skills could help people with IBD manage symptoms and day-to-day quality of life without relying solely on...

This preclinical study suggests a heat‑inactivated probiotic strain reduced colitis signs in mice and changed gut microbes and inflammatory pathways—findings that could inform future research into microbiome‑based or...

This preclinical study suggests a specific probiotic strain (Lp05) can increase regulatory T cells and reduce inflammation in a mouse colitis model, which could point to new microbiome-based approaches for IBD in the...

Metabolic interactions between epithelial and immune cells may help explain persistent inflammation and barrier problems in IBD and point to new therapeutic targets that could complement current immune-targeting drugs.

The review links changes in the microbiome and microbial polyamine production to immune cell imbalance that can drive both oral inflammation and IBD. Understanding this pathway could point to new research directions and...

ER stress may be a pathway connecting what people eat with intestinal inflammation in IBD. Understanding this could eventually help tailor diets or develop therapies, but human evidence is still limited.

Microbiome composition differed between relapse and remission in ulcerative colitis in this study; specific bacterial and fungal taxa were statistically associated with clinical and endoscopic activity and are proposed...

The intestinal mucosal barrier is central to ulcerative colitis. If probiotics can strengthen that barrier, they might reduce inflammation or help maintain remission. This review summarizes mechanistic and early clinical...

Fatigue markedly affects quality of life for people with Crohn’s and often remains after inflammation is controlled. Recognizing multiple drivers — psychological distress and immune/hematologic signals — could change how...

If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...

m6A RNA methylation is a regulator of RNA function that may influence inflammation, immunity, and the intestinal microbiota — all central to IBD. Understanding these pathways could identify new biomarkers or drug targets...

This study describes a novel, non‑drug HA‑based nano‑assembly that targets inflammatory M1 macrophages and reshapes the colonic immune environment in mouse models of ulcerative colitis — a potential new therapeutic...

This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or...

This study describes an engineered probiotic that senses a validated IBD inflammation biomarker (calprotectin) and produces IL‑2 locally, offering a potential new way to deliver anti‑inflammatory therapy on demand.